Skip to main content

Table 2 Mixed relative treatment effects of major adverse cardiovascular event and composite renal events among urate lowering agents

From: Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials

MACE; RR (95% CI)

Rasburicase

-

-

-

1.69

(0.79, 3.63)

Febuxostat

0.82

(0.52, 1.32)

0.62

(0.35, 1.11)

2.92

(1.25, 6.78)

1.72

(0.94, 3.17)

Allopurinol

0.75

(0.47, 1.21)

1.14

(0.59, 2.22)

0.68

(0.46, 0.99)

0.39

(0.23, 0.66)

Placebo/no ULT

Composite renal events; RR (95% CI)

  1. CI Confidence interval, MACE Major adverse cardiovascular events, RR Risk ratio, ULT, Urate-lowering therapy agents
  2. Comparisons are read from left to right for both MACE and composite renal events. For example; allopurinol had lower composite renal events with RR (95% CI) of 0.39 (0.23, 0.66) compared with placebo/no ULT, and lower MACE with RR (95% CI) of 0.75 (0.47, 1.21) compared with placebo/no ULT
  3. Bold font indicates statistical significance
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us